| 词条 | Trafermin |
| 释义 |
| Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = | image = | width = | tradename = Fiblast | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Topical (spray)[1] | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 131094-16-1 | CAS_supplemental = | class = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChemSubstance = 17397511 | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = none | UNII = 333OX80X87 | KEGG = D03362 | ChEBI = | ChEMBL = | C=764 | H=1201 | N=217 | O=219 | S=6 | molecular_weight = 17122.4232 g/mol | SMILES = | StdInChI_Ref = | StdInChI = | StdInChIKey_Ref = | StdInChIKey = | synonyms = CAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced) }}Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.[1][2][3] It is also currently in preregistration for the treatment of periodontitis.[1][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.[5][6] The drug has been marketed in Japan since June 2001.[7] References1. ^1 http://adisinsight.springer.com/drugs/800009962 2. ^https://www.drugs.com/international/trafermin.html 3. ^1 {{cite book|author=Seung-Kyu Han|title=Innovations and Advances in Wound Healing|url=https://books.google.com/books?id=IY-QCgAAQBAJ&pg=PA206|date=15 September 2015|publisher=Springer|isbn=978-3-662-46587-5|pages=206–}} 4. ^{{cite journal | vauthors = Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M, Kunimatsu K, Shimauchi H, Ogata Y, Yamamoto M, Nakagawa T, Sato S, Ito K, Ogasawara T, Izumi Y, Gomi K, Yamazaki K, Yoshie H, Fukuda M, Noguchi T, Takashiba S, Kurihara H, Nagata T, Hamachi T, Maeda K, Yokota M, Sakagami R, Hara Y, Noguchi K, Furuuchi T, Sasano T, Imai E, Ohmae M, Koizumi H, Watanuki M, Murakami S | title = Randomized Placebo-Controlled and Controlled Non-Inferiority Phase III Trials Comparing Trafermin, a Recombinant Human Fibroblast Growth Factor 2, and Enamel Matrix Derivative in Periodontal Regeneration in Intrabony Defects | journal = J. Bone Miner. Res. | volume = 31 | issue = 4 | pages = 806–14 | year = 2016 | pmid = 26547659 | doi = 10.1002/jbmr.2738 | url = }} 5. ^{{cite book |author1= Kim E. Barrett |author2= Fayez K. Ghishan |author3= Juanita L. Merchant |author4= Hamid M. Said, Jackie D. Wood |title= Physiology of the Gastrointestinal Tract |url= https://books.google.com/books?id=CNwLlih2C60C&pg=PA216 |date=10 May 2006 |publisher= Academic Press |isbn= 978-0-08-045615-7 |pages=216–}} 6. ^{{cite book|author=Hamid M. Said|title=Physiology of the Gastrointestinal Tract, Two Volume Set|url=https://books.google.com/books?id=ytWBLAy1FGQC&pg=PA235|date=4 July 2012|publisher=Academic Press|isbn=978-0-12-382027-3|pages=235–}} 7. ^Spaccapelo, L. RATIONALE FOR BASIC FGF IN WOUND HEALING AND REVIEW OF THERAPEUTIC APPLICATIONS. External links
3 : Growth factors|Human proteins|Recombinant proteins |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。